Pot Mental Health Warnings? ‘Breakthrough’ VR Therapy; Eye Test for ADHD

Pot Mental Health Warnings? ‘Breakthrough’ VR Therapy; Eye Test for ADHD

California might start labeling marijuana products with warnings about mental health risks. (NPR)

The FDA granted a breakthrough device designation to OxfordVR’s gameChange virtual reality cognitive therapy for serious mental illness.

The investigational Alzheimer’s disease drug fosgonimeton flopped in a phase II study, failing to significantly change biomarker ERP P300 latency in those with mild-to-moderate disease, Athira Pharma announced.

Among individuals with type 2 diabetes who were smoking at least 10 cigarettes a day, 1 mg of varenicline (Chantix) twice daily helped more people achieve smoking abstinence. (JAMA Network Open)

An eye test involving full-field light-adapted electroretinograms was able to help distinguish between ADHD and autism spectrum disorder in youth. (Frontiers in Neuroscience)

How early in life do children need psychological support? (Philadelphia Inquirer)

Mindset Pharma announced it partnered with Toronto-based Center for Addiction and Mental Health to test a novel second-generation psilocybin-like compound.

Excitatory noninvasive brain stimulation protocols over the left dorsolateral prefrontal cortex were linked with large improvements in negative symptom severity for patients with schizophrenia, according to a network meta-analysis in JAMA Psychiatry.

  • Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.

Leave a Comment

Your email address will not be published.